ReviewCurrent heart failure reports2026
Female Fingerprint: Sex-Specific Aspects in Patients With Atrial Fibrillation and Heart Failure.
Review in Current heart failure reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAtrial fibrillation (AF) and heart failure (HF) frequently coexist and represent a major source of cardiovascular morbidity and mortality. This review summarizes current evidence on sex-specific differences in epidemiology, pathophysiology, clinical presentation, prognosis, and treatment in women with AF and HF. RECENT
findingsEmerging evidence indicates that women with AF and HF constitute a distinct clinical and biological phenotype. Women typically develop AF at older age, more commonly present with hypertension and HF with preserved ejection fraction (HFpEF), and report greater symptom burden and impaired quality of life. Sex-specific mechanisms including hormonal influences, atrial fibrosis, endothelial dysfunction, inflammation, autonomic dysregulation, and microvascular disease contribute to these differences. Population studies further demonstrate sex-related disparities in HF development and outcomes across AF subtypes. Despite increasing awareness, women remain underrepresented in clinical trials and are less likely to receive rhythm-control strategies, catheter ablation, or device therapy. Recognition of the "female fingerprint" in AF and HF is essential for individualized risk stratification and the advancement of precision cardiovascular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.